STAT3 and B-cell non-Hodgkin lymphoma: More direct STAT3 inhibitors are in development, such as the dual-function molecule CpG-STAT3dODN, which consists of a TLR9 (Toll like receptor) agonist (CpG7909) and a STAT3 inhibitor, high-affinity decoy oligodeoxynucleotide for B-cell lymphoma immunotherapy [59].